Section
The Week
Weekly roundup of what mattered and why
The Week
Vertex and CRISPR Therapeutics just set the rare disease market’s new reference price with exa-cel. The fallou…
The Week
Billions move on Alzheimer's, Pfizer's oncology surprises, and new NIH rules shake the industry's R&D funding …
The Week
Merck’s Harpoon acquisition, an FDA rebuke for Eli Lilly, and divergent Q2 earnings forced the industry to rep…
The Week
The biggest stories from the week of March 10-14, 2025: supply chain expansion, regulatory escalation, and a p…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.